Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOVA22007
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
NOVA22007 is a proprietary cyclosporine A ophthalmic cationic emulsion developed for treating eye conditions including vernal keratoconjunctivitis (VKC) and dry eye syndrome. It utilizes Novasorb® cationic emulsion technology to enable optimal penetration of cyclosporine A into eye surface tissues.
- Brand names
- RestasisVerkazia
- Other names
- Ciclosporin
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on NOVA22007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOVA22007.